Shots:

• Roche acquires Spark Therapeutics- in all stock transaction for $114.50 /share in cash- making the total deal value $4.3B. Spark to receive premium of 122% based on its last day closing share price value i.e 22 February 2019
• The focus of the acquisition is to expand Roche’s footprints in genetic disorders including blindness- hemophilia- lysosomal storage disorders and neurodegenerative diseases
• Spark therapeutics’ portfolio includes SPK-8011 & SPK-8016 for hemophilia A- SPK-9001 for haemophilia B- SPK-3006 for Pompe disease- SPK-1001 for CLN2 disease and Luxturna (voretigene neparvovec-rzyl) approved for confirmed biallelic RPE65 mutation-associated retinal dystrophy. The transaction is expected to close in the Q2’19  

Ref: Roche | Image: Roche